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Abstract
Background: MAP2K4 is a putative tumor and metastasis suppressor gene frequently found to be deleted in
various cancer types. We aimed to conduct a comprehensive analysis of this gene to assess its involvement in
ovarian cancer.
Methods: We screened for mutations in MAP2K4 using High Resolution Melt analysis of 149 primary ovarian
tumors and methylation at the promoter using Methylation-Specific Single-Stranded Conformation Polymorphism
analysis of 39 tumors. We also considered the clinical impact of changes in MAP2K4 using publicly available
expression and copy number array data. Finally, we used siRNA to measure the effect of reducing MAP2K4
expression in cell lines.
Results: In addition to 4 previously detected homozygous deletions, we identified a homozygous 16 bp truncating
deletion and a heterozygous 4 bp deletion, each in one ovarian tumor. No promoter methylation was detected.
The frequency of MAP2K4 homozygous inactivation was 5.6% overall, and 9.8% in high-grade serous cases.
Hemizygous deletion of MAP2K4 was observed in 38% of samples. There were significant correlations of copy
number and expression in three microarray data sets. There was a significant correlation between MAP2K4
expression and overall survival in one expression array data set, but this was not confirmed in an independent set.
Treatment of JAM and HOSE6.3 cell lines with MAP2K4 siRNA showed some reduction in proliferation.
Conclusions: MAP2K4 is targeted by genetic inactivation in ovarian cancer and restricted to high grade serous and
endometrioid carcinomas in our cohort.
Background
Mitogen-activated protein kinase kinase 4 (MAP2K4) is a
gene encoding a member of the MAP kinase signalling
family [1,2]. This 399 amino acid protein is a compo-
nent of a triple kinase cascade whereby activated MAP
kinases are successively phosphorylated to mediate cel-
lular responses to cytokine signals, stress and other
extracellular stimuli [3]. The phosphorylation cascade is
initiated by the activation of MAP3K proteins, such as
MEKK and MLK, which phosphorylate MAP2K4. In its
activated state, MAP2K4 can phosphorylate JNK or p38
with dual specificity, resulting in the activation of the
stress activated protein kinase (SAPK) pathway, which
has been associated with apoptosis and neoplastic trans-
formation [4,5]. However, the response initiated through
the activation of JNK or p38 appears to be highly con-
text dependent. For example, prolonged JNK activation
has been demonstrated to induce an apoptotic effect in
certain neuronal cells independent of c-Jun [6,7]. How-
ever, transient JNK activation in response to physiologi-
cal stimuli does not elicit neuronal apoptosis, reflecting
a dependence upon other factors to activate the JNK-
mediated apoptotic pathway [8].
The genetic evidence for a role of MAP2K4 in cancer
is gathering strength. It wasi n i t i a l l yd e s c r i b e da sa
tumor suppressor gene (TSG), with a low frequency of
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types [9]. In recent high-throughput sequencing and
copy number studies, MAP2K4 appears to be only very
rarely targeted by base pair level mutation but is consis-
tently identified as a common target for deletion, includ-
ing homozygous deletion [10-12]. While some of these
deletions may be a consequence of LOH targeting the
nearby TP53 gene on 17q12, in a few instances there are
homozygous deletions that appear to target only
MAP2K4. Despite this genetic support for a tumor sup-
pressor role, functional studies have generated mixed
results. One experimental model demonstrated that over-
expression of MAP2K4 could reduce the incidence and
onset of metastasis in ovarian and prostate cancer cell
lines [13]. However, in contrast, overexpression and
silencing of the gene in a different cellular context was
found to support a pro-oncogenic role for MAP2K4 [14].
In ovarian cancer, in addition to the apparent role of
MAP2K4 in metastasis suppression, there have been
limited data showing loss of expression and genetic
aberrations in several small cohorts [15-17]. Gene
expression by immunohistochemistry and quantitative
PCR was found to be reduced in cancer samples com-
pared to normal or benign ovarian tissue. The only
study to examine epigenetic control of MAP2K4 in any
cancer type was performed on a small number of ovar-
ian cancer cases, and did not find any evidence for pro-
moter methylation [16]. We have previously reported
that recurrent homozygous deletions appear to specifi-
cally target MAP2K4 in primary ovarian tumors, and the
gene lay in a minimal region of loss of heterozygosity
(LOH) in 68% (72/106) of the cases, the second most
frequent locus targeted by LOH [18]. Despite this accu-
mulating evidence, the status of MAP2K4 as a tumor
suppressor in ovarian cancer is equivocal and therefore
in this study we have undertaken a comprehensive ana-
lysis of mutation, methylation and gene knockdown.
Methods
Clinical specimens
One hundred and sixty one tumor tissue samples (77
serous, 21 mucinous, 33 endometrioid, 8 clear cell and
22 other, Additional file 1, Table S1) were obtained
from patients presenting to hospitals in the south of
England, UK or at the Peter MacCallum Cancer Centre,
Australia. DNA was extracted either from whole tissue
or from samples that were manually needle microdis-
sected to ensure they contained >85% epithelial tumor
cells. RNA was extracted from microdissection of subse-
quent 10 μm sections using the mirVana miRNA Isola-
tion Kit (Ambion Inc, Austin, TX). Normal DNA was
extracted from matching peripheral blood samples as
described previously [19]. DNA for mutation screening
underwent whole genome amplification (WGA) using
the Repli-G Phi-mediated amplification system as
described previously [20]. Institutional ethics commit-
tees approved this study.
Mutation screening of MAP2K4 using High Resolution
Melt (HRM)
Primers were designed to amplify each exon and the
intron/exon boundaries of the MAP2K4 coding sequence
using the software packages ExonPrimer and Primer3
[21], except for exon 11, which used previously published
primers [12]. Exon 7 was covered by two overlapping pri-
mer pairs. Exon 1 was not analyzed as the PCR could not
be optimized to amplify a specific product, despite multi-
ple different primer sets, most likely because of the high
GC content. Exon 1 contains 114 bp of coding sequence
and has similarly been excluded from other mutation
screening studies [12,22]. Primer sequences and amplifi-
cation conditions are listed in Additional file 2, Table S2.
HRM using PCR products amplified from WGA template
DNA and DNA sequencing were carried out as described
previously [20]. Somatic alterations were confirmed by
re-sequencing from non-WGA tumor DNA and the
matching normal DNA.
MAP2K4 promoter methylation analysis by Methylation-
Specific Single Strand Conformation Polymorphism (MS-
SSCP) and bisulfite sequencing
The MAP2K4 CpG island was amplified using previously
published oligonucleotides [16]. DNA samples were
bisulphite treated using the MethylEasy Xceed Rapid
DNA Bisulphite Modification kit (Human Genetic Signa-
tures, Sydney, Australia) following the manufacturer’s
instructions. After PCR amplification, products were ana-
lyzed by SSCP using the ABI 3130 Genetic Analyzer
(Applied Biosystems, Foster City, CA) as described pre-
viously [20], with SssI methylase-treated normal DNA
used as a positive control for CpG island methylation.
Normal DNA samples were treated using CpG methyl-
transferase SssI (New England Biolabs, Ipswich, MA),
which methylates all CpGs before bisulfite treatment.
Samples showing a shift in mobility were sequenced as
described above.
Knock-down of MAP2K4 in cell culture
Reagents for transient gene knockdown were obtained
from Dharmacon (Thermo Fisher Scientific, Lafayette,
CO), comprising the siRNA SMARTpools for MAP2K4
(L-003574-00) and a non-targeting control siRNA
(D-001810-0X). This analysis was performed using the
JAM and HOSE6.3 ovarian cell lines. The JAM cell line
is a derivative of a poorly differentiated serous cystade-
nocarcinoma [23], while the HOSE6.3 cell line has been
established by E6/E7 immortalisation of human ovarian
surface epithelial cells [24].
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sity of 3.0 x 10
3 per well. Each cell line was reverse trans-
fected [25]with 25 nmol/l of siRNA and the appropriate
transfection reagent diluted in Optimem
® serum free
medium (Invitrogen, Carlsbad, CA). HOSE 6.3 was trea-
ted with 0.05 μl DharmaFECT 1 and JAM was treated
with 0.1 μl DharmaFECT 3. All transfections were per-
formed in triplicate and in three separate experiments.
Transfection efficiency was determined by quantitative
PCR (QPCR) whereby RNA was extracted from cells at
48 h post-transfection using the RNeasy Mini kit (Qia-
gen, Valencia, CA, USA), in accordance with the manu-
facturer’s instructions. Thereafter, cDNA was generated
from 100 ng of RNA using Superscript III VILO (Invi-
trogen, Carlsbad, CA), in accordance with the manufac-
turer’s instructions. Expression of MAP2K4 was assessed
using primers listed in Additional file 2, Table S2 on the
LightCycler
® 480 (Roche Diagnostics, Mannheim, Ger-
many). PCR was performed using the SYBRgreen QPCR
mix (Thermo Fisher Scientific, Lafayette, CO) and rela-
tive MAP2K4 gene expression was determined according
to the comparative CT (ΔΔCT)m e t h o d :ΔΔCT = ΔCT
MAP2K4 siRNA DNA - ΔCT Non-targeting siRNA
DNA. ΔCT (threshold cycles) is the CT of the reference
gene minus the CT of the target gene. Fold difference of
MAP2K4 expression was calculated by 2
-ΔΔCT. Hypox-
anthine phosphoribosyltransferase 1 (HPRT1) was used
as an endogenously expressed reference gene for the
purpose of quantifying relative gene expression. Each
QPCR was performed in triplicate using cDNA derived
from three independent experiments. Cellular prolifera-
tion was measured across a 7-day period according to
the reduction of alamarBlue reagent (Invitrogen, Cals-
bad, CA) following a 4 h incubation as described pre-
viously [26].
Statistical Analysis
Expression array files were imported into Partek Geno-
mics Suite v 6.4 (Partek, St. Louis, MO) using default
parameters including RMA normalization. These values
were then used for statistical tests. Cox regression analy-
sis was carried out in Partek Genomics Suite v 6.4. The
results published here are in part based upon data gener-
ated by The Cancer Genome Atlas pilot project estab-
lished by the NCI and NHGRI. Information about TCGA
and the investigators and institutions who constitute the
TCGA research network can be found at http://cancer-
genome.nih.gov. Other statistical analyses were carried
out using GraphPad Prism software v5 (GraphPad Soft-
ware, La Jolla, CA) and were considered significant at a
P-value of less than 0.05. In assessing differences in pro-
liferation, 2-way ANOVA was performed to interrogate
time points as categorical variables.
Results and Discussion
We previously reported MAP2K4 as a candidate tumor
s u p p r e s s o rg e n e[ 1 8 ]a f t e rS N Pa r r a yc o p yn u m b e ra n d
LOH data from 125 primary ovarian tumors identified
four homozygous deletions with a minimal point of
overlap of just 50 kb, which targeted two genes,
MAP2K4 and hsa-mir-744. In the current study we
decided to undertake further analysis of these genes to
assess the frequency of gene inactivation by means other
than deletion (the analysis of hsa-mir-744 will be
described elsewhere). We analyzed exons 2-11 of
MAP2K4 in 149 primary ovarian cancers using HRM
and DNA sequencing. We identified two somatic altera-
tions, a homozygous 16 bp deletion in exon 7 in a serous
ovarian tumor (Figure 1), and a heterozygous 4 bp dele-
tion in exon 3 in an endometrioid tumor. The 16 bp dele-
tion in IC489 causes a frameshift alteration that would
lead to protein termination 7 amino acids downstream
(p.Asp263fs). The mutation represented more than 70%
of the bases in the sequence trace, thus we consider it to
be homozygous, correlating with the SNP array data for
this tumor showing chromosome 17 LOH across the
MAP2K4 locus. The 4 bp deletion at the start of exon 3
would cause protein termination two amino acids down-
stream (p.Glu74fs) and is heterozygous in accordance
with the lack of LOH at the locus in IC128 by SNP array.
No known or novel polymorphisms were detected in
the coding region of MAP2K4, which is consistent with
the low number (n = 5) of reported coding variants
(dbSNP build 130, http://www.ncbi.nlm.nih.gov/projects/
SNP/). Consequently, the failure to detect variants
should not be attributed to a deficiency in the accuracy
of the method, which has been successfully utilised to
detect both novel and previously described polymorph-
isms in a similar context [20,27].
Combining the detection of mutation and deletion
data, the overall frequency of homozygous inactivation
of MAP2K4 was 5.6% (5/89 samples analysed by both
techniques). However, it was notable that cases with
genetic changes were either of the high-grade serous
(4/5) or grade 3 endometrioid (1/5) subtypes. As a pro-
portion of these subtypes, inactivation of MAP2K4 was
9.8% (4/41) and 4.8% (1/21), respectively. We also ana-
l y z e dc o p yn u m b e rd a t af r o mT h eC a n c e rG e n o m e
Atlas (TCGA), a public data set of mostly high-grade
serous ovarian tumors (http://cancergenome.nih.gov). In
157 SNP6.0 arrays, we identified a further 3 homozy-
gous deletions, two of which specifically targeted only
MAP2K4. TCGA has undertaken mutation screening by
sequencing on 24 samples to date with no somatic
alterations identified.
We had previously observed a decrease in MAP2K4
RNA expression in samples with LOH at the locus [18].
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bisulfite sequencing to assess whether this reduction in
expression was mediated by epigenetic mechanisms
(Figure 2). We did not detect any electrophoretogram
shifts in any tumor DNA that would indicate methyla-
tion in this region, in contrast to the positive SssIt r e a -
ted control DNA. This was confirmed by selecting a few
samples for sequencing. Consequently, methylation does
not appear to be a mechanism by which MAP2K4 is
silenced in ovarian cancer. In contrast, there was a high
proportion of samples exhibiting LOH in conjunction
with copy number loss at the MAP2K4 locus [18]. 56%
of samples with LOH (38% of samples overall) were sub-
ject to copy number loss, indicating that MAP2K4 may
be targeted by this genetic mechanism. In a recent copy
number analysis [28] we found that 164/398 (41%) ovar-
ian carcinomas of primarily serous/endometrioid sub-
type showed at least hemizygous copy number loss at
MAP2K4. In addition, there was a strong correlation
between copy number and gene expression in three
microarray data sets of high grade serous/endometrioid
ovarian carcinoma (Additional file 3, Figure S1): our
own ([29]; r = 0.46, p = 0.001, n = 47), Etemadmogha-
dam et al., ([30]; r = 0.59, p < 0.0001, n = 79), and
TCGA (r = 0.51, p < 0.0001, n = 157). Therefore, the
loss of MAP2K4 expression may be largely attributable
to genomic loss, rather than epigenetic mechanisms of
gene regulation.
To assess the impact of reduced MAP2K4 expression
we used the full TCGA data (n = 400 with outcome
data) and another published data set ([31], n = 207) to
investigate any association with clinical outcome in inva-
sive ovarian carcinoma (Additional file 4, Figure S2).
Both data sets were comprised of primarily high-grade
serous carcinomas. In a Cox regression analysis includ-
ing age and residual disease as co-factors in the model,
low expression of MAP2K4 was associated with
improved overall survival in the Tothill data set (P =
0.031, hazards ratio = 1.7), but was not significant in the
TCGA data set (P = 0.75). Expression of MAP2K4 was
not significant in either data set when progression free
survival was considered. When viewing this data using a
Kaplan-Meier plot having split the samples based on
quartiles of expression values ,t h ed i f f e r e n c ei ns u r v i v a l
was associated only with the bottom quartile (low
expressors) in the Tothill data set.
To measure the effect of reduced MAP2K4 expression,
we knocked down MAP2K4 in two cell lines using
siRNA and assessed cellular proliferation (Figure 3). We
used an immortalized cell line derived from human
ovarian surface epithelium (HOSE6.3 [24]). While this
line is not normal, it is non-tumorigenic and should
have fewer disrupted pathways or additional genetic
lesions than the cancer cell lines used previously. For
comparison, we selected a cell line established in culture
from an ovarian tumor xenograft, JAM [23], which
Figure 1 Somatic alteration of MAP2K4 in ovarian cancer. A. Homozygous deletions (red bars) over the MAP2K4 region detected by
Affymetrix SNP array. B. An aberrant shift was detected by HRM (red trace) compared with the matching normal DNA and the other tumor
samples (blue traces). C. The sequence trace of re-amplified, non-WGA tumor DNA (IC489T) compared to normal (IC489N) shows a 16 bp
homozygous deletion in exon 7 (red box), which causes a frameshift alteration leading to premature termination of the protein as indicated by
the sequence below.
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Page 4 of 7Figure 2 Aberrant promoter hypermethylation is rare in the MAP2K4 promoter region.A .M a po fMAP2K4 promoter region from UCSC
Genome browser (Mar. 2006 build) showing the gene in blue (exon 1 indicated by thicker bar), predicted CpG island in green, location of all
CpG dinucleotides in orange, and location of the primers and MS-SSCP PCR product in black. MS-SSCP (B) and DNA sequencing
electrophoretograms (C) for a representative tumor sample lacking methylation (top) and the positive methylation control SssI treated normal
lymphoblast DNA.
Figure 3 Loss of MAP2K4 expression affects cellular proliferation. Cellular proliferation was assessed using alamarBlue dye measured by
fluorescence at 540/610 nm. Each of three experiments was performed in triplicate and normalized to the 24 h time-point. The average of three
biological replicates is shown, except for the 168 h time-point, which was only done twice. Statistical significance was determined by 2-way
ANOVA. Error bars are representative of SEM, n = 3.
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Page 5 of 7expresses high levels of MAP2K4. Expression of
MAP2K4 in transfected cells was evaluated at 48 h post-
transfection by QPCR in each of the assays performed
(Additional file 5, Figure S3). In each case, highly effi-
cient gene silencing was observed, with at least 75%
silencing of MAP2K4 expression in both cell lines ana-
lyzed. Cellular proliferation and metabolism was mea-
sured across a seven-day period. Both JAM and
HOSE6.3 showed some reduction in cell number over
this time course in the cells treated with MAP2K4
siRNA, however this was only significant for the JAM
c e l l s( P=0 . 0 0 1 ,2 - w a yA N O V A ) .Ar e c e n ts t u d yu s e da
stable RNAi system to knock down expression of
MAP2K4, and was able to select clones with reduced
MAP2K4 expression, suggesting that loss of the gene
may not always adversely affect cell viability or prolifera-
tion [32]. In this system the study found that MAP2K4
inactivation correlated with increased invasiveness
through the induction of the epithelial to mesenchymal
transition (EMT). Another recent study found that ecto-
pic expression of MAP2K4 mutants increased ancho-
rage-independent growth in NIH3T3 cells [33]. The
effect of MAP2K4 gene knockdown may therefore be
dependent on the in vitro experimental system used,
perhaps not surprisingly given the role of the protein in
such a complex signalling network.
Conclusions
In summary, we have conducted a comprehensive analy-
sis of mutation, methylation, expression and gene
knockdown of MAP2K4 in ovarian cancer. We did not
detect any methylation at the MAP2K4 promoter in
ovarian tumour tissue, consistent with one other study
to date [16]. We did find genetic alterations confirming
MAP2K4 as a tumour suppressor gene for ovarian can-
cer in a subset of high grade serous and endometrioid
cases, including a specific 16 bp homozygous deletion in
exon 7 as well as larger homozygous deletions. In addi-
tion, we found that MAP2K4 was frequently targeted by
hemizygous deletion and that this correlated with
decrease in gene expression in several independent ovar-
ian cancer data sets.
Additional material
Additional file 1: Table S1 Clinical samples analyzed in the
mutation and methylation screens
Additional file 2: Table S2 Oligonucleotide primer sequences
Additional file 3: Figure S1 Correlation of copy number with
expression for MAP2K4. Three data sets are shown: Ramakrishna
Gene1.0ST/SNP6.0 data [29], TCGA U133A/SNP6.0, and Etemadmoghadam
U133Plus2/50K data [30]. For the U133 platforms probeset 203266_s_at is
shown. Copy number is taken from the average copy number value of
SNPs within the segment of lowest copy number intersecting with the
MAP2K4 gene. R and p values for Pearson’s correlation.
Additional file 4: Figure S2 Overall survival of ovarian cancer
patients relative to MAP2K4 expression. A. Partek output for Cox
regression analysis in the Tothill data set of MAP2K4 expression probeset
203266_s_at, including patient age and residual disease as co-factors. B.
Kaplan-Meier curves, showing difference in survival of patients with low
MAP2K4 expression (bottom quartile of cases, red solid line) compared to
all remaining cases (blue dashed line) from Tothill et al., 2008 and The
Cancer Genome Atlas (TCGA). Graphs truncated at 150 months. P value
shown is the log rank (Mantel-Cox) test.
Additional file 5: Figure S3 Reduction in MAP2K4 expression
following siRNA knockdown
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